Table 4 Clinical characteristics of study population after propensity score matching for all patients
Variables, n (%) or mean ± S.D (range) | Entecavir N = 115 | TAF N = 83 | p value |
|---|---|---|---|
Age (years) | 55.1 ± 10.8 | 55.5 ± 9.8 | 0.783 |
Gender (male: female), n | 38:77 | 34:49 | 0.253 |
Use of rituximab, n (%) | 11 (9.6%) | 6 (7.2%) | 0.563 |
Use of steroid, n (%) | 11 (9.6%) | 4 (4.8%) | 0.213 |
Use of anthracycline, n (%) | 40 (34.8%) | 25 (30.1%) | 0.491 |
Hematologic malignancy, n (%) | 12 (10.4%) | 10 (12%) | 0.722 |
Distal metastasis, n (%) | 17 (14.8%) | 16 (19.3%) | 0.402 |
AST (U/L) | 32.9 ± 46.9 | 28.14 ± 19.5 | 0.412 |
ALT (U/L) | 39.8 ± 83.0 | 31.6 ± 32.3 | 0.390 |
Total bilirubin (mg/dL) | 0.63 ± 0.39 | 0.71 ± 0.46 | 0.190 |
Platelet × 103/μL | 250.2 ± 81.2 | 250.3 ± 102.7 | 0.996 |
FIB-4 | 1.33 ± 0.73 | 1.42 ± 0.91 | 0.436 |
HBV DNA (log10 IU/mL) | 2.84 ± 1.60 | 2.80 ± 1.54 | 0.861 |
Treatment duration (weeks) | 58.2 ± 18.3 | 55.7 ± 18.6 | 0.340 |
Consolidation duration (weeks) | 31.7 ± 10.7 | 31.1 ± 10.8 | 0.675 |